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Abstract
Introduction: Breast cancer is a complex disease and may be sub-divided into hormone-responsive (estrogen
receptor (ER) positive) and non-hormone-responsive subtypes (ER-negative). Some evidence suggests that
heterogeneity exists in the associations between coffee consumption and breast cancer risk, according to different
estrogen receptor subtypes. We assessed the association between coffee consumption and postmenopausal breast
cancer risk in a large population-based study (2,818 cases and 3,111 controls), overall, and stratified by ER tumour
subtypes.
Methods: Odds ratios (OR) and corresponding 95% confidence intervals (CI) were estimated using the multivariate
logistic regression models fitted to examine breast cancer risk in a stratified case-control analysis. Heterogeneity
among ER subtypes was evaluated in a case-only analysis, by fitting binary logistic regression models, treating ER
status as a dependent variable, with coffee consumption included as a covariate.
Results: In the Swedish study, coffee consumption was associated with a modest decrease in overall breast cancer
risk in the age-adjusted model (OR> 5 cups/day compared to OR≤ 1 cup/day: 0.80, 95% CI: 0.64, 0.99, P trend = 0.028).
In the stratified case-control analyses, a significant reduction in the risk of ER-negative breast cancer was observed
in heavy coffee drinkers (OR> 5 cups/day compared to OR≤ 1 cup/day : 0.43, 95% CI: 0.25, 0.72, P trend = 0.0003) in a
multivariate-adjusted model. The breast cancer risk reduction associated with higher coffee consumption was
significantly higher for ER-negative compared to ER-positive tumours (P heterogeneity (age-adjusted) = 0.004).
Conclusions: A high daily intake of coffee was found to be associated with a statistically significant decrease in ER-
negative breast cancer among postmenopausal women.
Introduction
Coffee is one of the most popular beverages in the
world. The latest coffee trade statistics estimated that
world coffee production amounted to 7.4 billion kg in
2009/2010 [1]. In Sweden, where coffee consumption is
among the highest in the world, the average coffee con-
sumption in 2008 was 8.2 kg per person [1,2], with a
median of three cups per person per day.
Coffee is interesting in the light of breast cancer etiol-
ogy because of its complex make-up of chemicals, sev-
eral of which have been shown in experimental studies
to have cancer risk altering potential through meaning-
ful biological mechanisms. The scientific community,
however, stands divided over toxicity of the beverage. It
has been demonstrated in experimental and clinical stu-
dies that coffee, being a complex mixture of caffeine
and polyphenols [3-7], can play a dual role as both a
carcinogen, in which it inhibits cellular repair of DNA
or enhances cell proliferation [8-11], and a chemo-pre-
ventive agent with anti-oxidative and weakly estrogenic
properties [12,13]. The bulk of previous studies suggest
that high coffee consumption is associated with a mod-
est reduction of breast cancer risk [14,15], although a
meta-meta-analysis of over 500 papers relating the con-
sumption of coffee to cancer of various sites by Arab
[16] reported a null association with breast cancer risk.
Breast cancer is a complex disease and may be sub-
divided into hormone-responsive (estrogen receptor
(ER) positive) and non-hormone-responsive subtypes
(ER-negative). Coffee itself might contain compounds
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subtypes. We, thus, hypothesize that heterogeneity exists
between coffee consumption and breast cancer risks for
ER-positive and ER-negative breast cancers.
In this study, we examine the association between cof-
fee consumption and postmenopausal breast cancer risk
in a large population-based study (2,818 cases and 3,111
controls), overall and stratified by hormone receptor sta-
tus. As the possibility that the weak relationship between
high levels of coffee consumption and the occurrence of
breast cancer is due to confounding by related dietary or
lifestyle factors is tenable [17], we also adjusted for these
factors in our final multivariate models.
Materials and methods
Subjects
Subjects were drawn from a population-based case-con-
trol study, which has been described in detail previously
[18]. The parent study consisted of women aged 50 to
74 years, born in Sweden and resident there between 1
October 1993 and 31 March 1995. An attempt was
made to contact all incident cases of invasive breast can-
cer in this population. Cases were identified through six
Swedish regional cancer registries, and written consent
to be approached with a mailed questionnaire was
requested from the women through their physicians.
The participation rate, amongst 3,979 eligible cases
detected, was 84%. Non-participation was attributed to
either refusal by the physician (4%) or the patient (12%).
Controls were frequency-matched to the cases by age.
Of 4,188 controls who were randomly selected from a
continuously updated Swedish register, 3,454 (82%) gave
consent to participate in the study. Exclusions were
made for women who were pre-menopausal (198 cases,
152 controls), or with unknown menopausal status (217
cases, 100 controls), or with a previous diagnosis of can-
cer (other than non-melanoma skin cancer or cancer in
situ of the cervix) (112 cases, 91 controls). The final
study group consisted of 2,818 cases and 3,111 controls.
The ethical review board at the Karolinska Institute and
the six ethical review boards in other regions of Sweden
approved the study.
For the validation analysis, subjects were drawn from
the population-based case-control MARIE (Mamma
Carcinoma Risk factor Investigation) study which was
carried out from August 2002 to September 2005 in two
s t u d yr e g i o n si nG e r m a n y( t h eH a m b u r ga n dR h e i n -
Neckar-Karlsruhe regions). Details of the study design
can be found in Flesch-Janys et al. [19]. Briefly, the
MARIE study included 3,464 postmenopausal and histo-
logically confirmed incident breast cancer cases aged 50
to 74 at diagnosis with primary invasive or in situ
tumours (International Classification of Diseases (ICD)
10: C50 and D05) and 6,657 controls, frequency
matched by year of birth and study region. Two controls
per case were randomly selected from the lists of resi-
dents provided by the population registries. For the pre-
sent analysis, in situ cases were excluded. The study was
approved by the ethics committees of the University of
Heidelberg and the University of Hamburg. All study
participants gave written informed consent.
Data collection
Data were obtained by meanso fa ne x t e n s i v em a i l e d
questionnaire requesting detailed information on estab-
lished and possible breast cancer risk factors, including
reproductive and menstrual history, family history of
breast cancer, hormone replacement therapy (HRT) and
anthropometric measures, such as body mass index
(BMI). Information on lifestyle such as smoking (> 1 year
or > 100 cigarettes), alcohol intake (g/day) and physical
activity (none, less than one hour per week, one to two
hours per week or more than two hours per week) was
also collected from the questionnaire. Highest education
level attained was available as a categorical variable (ele-
mentary school, junior secondary school, high school or
university). Data on the consumption of coffee one year
prior to interview, specified in cups per week, where a
cup was equivalent to 1.5 dl, were also collected. Age at
menopause was defined as the age of the last menstrual
period or age at bilateral oophorectomy, if one year or
more prior to data collection. The women were consid-
ered pre-menopausal if menopause occurred less than
one year before data collection. Women with hysterect-
omy, menses due to HRT or missing information were
considered post-menopausal if they had reached the 90
th
percentile of the age of natural menopause (54 years in
current smokers and 55 years in non-smokers, regardless
of case/control status), or otherwise as unknown. Sub-
jects classified as post-menopausal in this manner (280
cases and 303 controls) were assigned an age at meno-
pause according to their case/control and current smok-
ing status corresponding to the mean age at natural
menopause in the respective groups.
Information regarding the retrieval of hormone recep-
tor status from the medical records of all participants
from surgical and oncological units throughout Sweden
has been presented in detail elsewhere [20,21]. Although
ER and PR content of breast tumours were routinely
measured in Sweden at the time of the study, this was
often not performed on tumours ≤ 1c mi ns i z ed u et o
lack of tumour tissue. Quantitative receptor content was
thus only available for 65.4% (1,835 women) of the
tumours for both ER and PR.
For the validation study (MARIE), information on
potential risk factors for breast cancer was obtained in
face-to-face interviews using a standardized questionnaire.
Nutritional data were collected using a food frequency
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in the year prior to date of diagnosis for cases and date of
food frequency questionnaire completion for controls. The
consumption of caffeine-containing coffee was calculated
in cups per day based on the information on both portion
size (non-consumer, 0.5, 1, 2, 3 cups) and frequency (non-
consumer, once per month or less, two to three times per
month, once per week, two to three times per week, four
to six times per week, once per day, twice per day, three to
four times per day, five times per day or more). The analy-
sis was limited to women who answered both questions
on portion size and frequency of caffeine containing coffee
consumption. The final study group comprised 5,395 con-
trols and 2,651 cases. Information on tumour characteris-
tics, such as ER and PR status, was obtained from medical
records.
Statistical analysis
The variable for coffee consumption was categorized as
follows: one cup or less per day; more than one to three
cups/day; more than three to five cups/day; five or more
cups/day. These categories were based on the distribu-
tion within the control group. Since very few women
abstained from coffee, we combined abstainers and low
consumers (one cup per day) into a single category.
Women who consumed one cup or less of coffee per
day served as the reference group for all regression
analyses.
Unconditional logistic regression models, adjusting for
the matching factor, age at enrolment in years (continu-
ous), were applied to evaluate if established or possible
breast cancer risk factors had (including coffee con-
sumption) significantly different distributions/means
(using the Wald test) between breast cancer cases and
controls in this study.
The relationships between coffee consumption and
other breast cancer risk factors were explored in the con-
trol population by treating coffee consumption as a cov-
ariate and using linear regression analysis for continuous
risk factor variables (age at menarche (years), age at
menopause (years), BMI (kg/m
2) and alcohol consump-
tion (g/day)), logistic regression analysis, for binary risk
factor variables (HRT, family history of breast cancer and
smoking) or proportional odds logistic regression, for
categorical risk factor variables (parity/age at first birth
(nulliparous; parous and age at first birth < 25 yr; parous
and age at first birth ≥ 25 yr and < 30 yr; parous and age
at first birth ≥ 30 yr), highest education level (elementary
school, junior secondary school, high school and univer-
sity), and recent physical activity (one year before enrol-
ment; none, less than one hour per week, one to two
hours per week, more than two hours per week)). The
Wald test was used to determine the statistical signifi-
cance of an overall linear trend for the association
between coffee consumption, treated as a semi-continu-
ous variable, and the breast cancer risk factor in the mod-
els fitted.
For models for breast cancer risk, covariates were con-
sidered to be potential confounders if they were found to
be associated with both coffee consumption and breast
cancer risk, and caused a shift of > 10% in estimates for
any coffee category when added to the model. ORs and
corresponding 95% CI were estimated for the multivari-
ate logistic regression models fitted to examine breast
cancer risk, overall, and stratified by ER and PR tumour
subtypes. Three models were fitted for each outcome:
adjusted for the matching factor (age at enrolment only),
adjusted for age at enrolment, HRT, smoking and educa-
tion, and adjusted for age at enrolment, HRT, smoking,
education and daily alcohol consumption. The Wald test
was used to determine the statistical significance of an
overall linear trend for the association between coffee
consumption, treated as a semi-continuous variable, and
the breast cancer risk.
Since ER and PR status are strongly correlated (logistic
regression P-value for association < 2.0 × 10
-16), we
assessed the extent to which coffee consumption drives
each of the two tumour characteristics, by fitting multino-
mial regression models for five outcomes (controls, ER-
negative and PR-negative, ER-negative and PR-positive,
ER-positive and PR-negative, ER-positive and PR-positive).
We compared a model without parameter restrictions to
models with parameters restricted such that coffee con-
sumption was only allowed to be associated with one
tumour characteristic at a time. Likelihood ratio tests, with
two degrees of freedom, were used to test the null hypoth-
esis that associations between coffee consumption and PR
status was due only to an association with ER or PR status.
Associations between coffee consumption and hor-
mone receptor status were evaluated in a case-only analy-
sis, by fitting binary logistic regression models (for ER
and PR status), treating ER or PR status as dependent
variables, with coffee consumption included as a covari-
ate. ORs and corresponding 95% CI were estimated for
each coffee consumption category. P-values representing
heterogeneity were obtained by performing one degree of
freedom trend tests, treating coffee consumption as a
semi-continuous variable. As there exists prior evidence
that certain tumour characteristics such as ER status are
associated with age at diagnosis [22], and that coffee con-
sumption is significantly associated with age at diagnosis
[23], every model fitted in the case-only analysis was also
adjusted for age at diagnosis in years (continuous).
The validation analysis based on the MARIE study
population was performed using Proc LOGISTIC in
SAS version 9.2 (SAS Institute, Cary, NC, USA). The
variable on coffee consumption was categorized in the
same way as in the Swedish study with women who
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ence group. Unconditional logistic regression models
were used to estimate ORs and corresponding 95% con-
fidence intervals. To test for trend, we treated the four
categories of cups per day as a continuous scored vari-
able in the model statement only.
All statistical computations for the Swedish study were
performed using R version 2.8 [24]. All P-values pre-
sented are two-sided tests of statistical significance at
the 5% level.
Results
Table 1 describes the characteristics of study subjects in
both the Swedish and MARIE study with respect to sev-
eral breast cancer risk factors. Age at menarche was
weakly but positively associated with the disease (P =
0.057 in Swedish samples and P = 0.0026 in MARIE
samples), a result consistent with the literature [25].
Family history of breast cancer, age at menopause, par-
ity, age of first birth, recent BMI, use of HRT, alcohol
consumption, physical activity and highest education
level attained were strongly significant for breast cancer
risk with effects in a direction consistent with those esti-
mated in other epidemiological studies. Smoking for
more than one year or more than 100 cigarettes was not
found to be associated with breast cancer risk in the
Swedish study (P = 0.176).
Table 2 summarizes the relationships between coffee
consumption and other breast cancer risk factors in
controls. The variables found to be significantly asso-
ciated with coffee consumption among controls were
HRT (P = 0.008), smoking (P < 0.0001) and highest edu-
cation level attained (0.041).
Table 3 shows the multivariate-adjusted OR estimates
and corresponding 95% CIs of postmenopausal breast
cancer for coffee consumption, overall and stratified by
breast cancer tumour subtype based on ER and PR status,
for the Swedish dataset. Results were shown for the fol-
lowing models: adjusted by the matching factor, age at
enrolment, in years (continuous) only, and potential con-
founders (HRT ever/never, ever smoked > 1 yr or > 100
cigarettes, and education (elementary school, junior sec-
ondary school, high school or university)) and average
daily alcohol consumption (g/day). A modest decrease in
overall breast cancer risk was observed for the models
adjusted for age only (OR>5c u p s / d a y :≤ 1c u p / d a y :0 . 8 0
((0.64, 0.99), P = 0.028). When the model was further
adjusted for HRT, smoking, education and average daily
alcohol consumption, the protective effect on overall
breast cancer risk was no longer found to be statistically
significant. In the stratified analyses, significant reduc-
tions in the risk of ER-negative and PR-negative subtypes
were observed, with the strongest effect being seen in
ER-negative subtypes, for all models examined (OR>5
cups/day: ≤ 1 cup/day for multivariate model: 0.43 (0.25, 0.72),
P = 0.0003).
We next tested for heterogeneity in the effects of cof-
fee consumption on hormone receptor status (ER and
PR) in the Swedish study. The breast cancer risk reduc-
tion associated with higher coffee consumption was sig-
nificantly higher for ER-negative compared to ER-
positive tumours (P heterogeneity (age-adjusted) =
0.004). The effect of coffee consumption was, however,
not significantly different by PR status (P heterogeneity
(age-adjusted) = 0.230). The fitted multinomial logistic
regression model (five categories; cases by ER/PR status
and controls) without parameter restrictions was not
found to perform better than the model with coffee con-
sumption effect, restricted to be independent of PR sta-
tus (P = 0.877). On the other hand, the unrestricted
model performed better than the model with coffee con-
sumption effect restricted to be independent of ER sta-
tus (P = 0.034).
Motivated by the trend test results in the ER-negative
cancers, we performed a validation analysis using the
MARIE study. Table 4 shows the corresponding multi-
variate-adjusted OR estimates and corresponding 95%
CIs of postmenopausal breast cancer for coffee con-
sumption, overall and stratified by breast cancer tumour
subtype based on ER and PR status, for the validation
performed using the MARIE study. A modest protective
effect of the same scale, but not reaching statistical sig-
nificance, was observed in the MARIE study (OR> 5 cups/
day: ≤ 1c u p / d a y : 0.87 (0.71, 1.07), P trend = 0.173).
Although the difference in overall effect sizes for differ-
ent breast cancer subtypes were less impressive in the
validation dataset, the strongest protective effect was
similarly observed for the ER-negative subtype (OR>5
cups/day: ≤ 1 cup/day: 0.67 (0.43, 1.05), P trend = 0.326), fol-
lowed by the PR-negative subtype (OR> 5 cups/day: ≤ 1 cup/
day: 0.70 (0.49, 1.00), P trend = 0.280). The ORs, corre-
sponding 95% CI, and P-values for trend were not
altered by the introduction of smoking, alcohol con-
sumption and other lifestyle factors.
Discussion
Our main finding was that coffee consumption was
associated with a strong reduction in breast cancer risk
for the ER-negative tumour subtype. This effect was
independent of HRT, smoking, highest education level
attained, and average daily alcohol consumption.
In the multivariate-adjusted Swedish study, women
who drank more than five cups of coffee per day were
57% (P = 0.0003) and 33% (P = 0.034) less likely to get
the ER-negative and PR-negative disease, respectively,
than the reference group. The effects were also found to
be independent of PR status. Motivated by the trend
test results of the ER-negative breast cancer subgroup
Li et al. Breast Cancer Research 2011, 13:R49
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Page 5 of 10Table 2 Associations of coffee consumption and breast cancer risk factors in Swedish study (controls only)
Breast cancer risk factors Daily coffee consumption
≤ 1 cup 2 to 3 cups 4 to 5 cups > 5 cups P trend
a
Age at menarche, continuous (y)
Mean (SD) 13.5 (1.5) 13.6 (1.4) 13.6 (1.4) 13.6 (1.5) 0.506
Controls (n) in each coffee consumption category 246 1,054 776 326
Age at menopause, continuous (y)
Mean (SD) 49.9 (4.1) 50 (4.1) 50 (3.8) 50.2 (3.6) 0.331
Controls (n) in each coffee consumption category 268 1,164 840 360
Body mass index, continuous (kg/m2)
Mean (SD) 25.4 (5.1) 25.4 (4) 25.4 (4) 25.4 (4.7) 0.979
Controls (n) in each coffee consumption category 264 1,158 840 362
Alcohol consumption (g/day)
Mean (SD) 2.1 (4.2) 2.2 (4.0) 2 (3.7) 2 (4.3) 0.411
Controls (n) in each coffee consumption category 252 1,056 761 327
Hormone replacement therapy
Proportion of ever users 0.46 0.44 0.42 0.37 0.008
269 1,160 843 361
Family history of breast cancer
Proportion with family history of breast cancer 0.11 0.10 0.09 0.08 0.281
Controls (n) in each coffee consumption category 266 1,154 830 353
Smoked > 1 year or > 100 cigarettes (No/Yes)
Proportion of Yes 0.37 0.37 0.47 0.57 < 0.0001
Controls (n) in each coffee consumption category 270 1,170 846 363
Parity/Age at first birth, categorical
Proportion of nulliparous 0.14 0.12 0.09 0.10 0.876
Proportion of parous with age of first birth < 25 y 0.42 0.47 0.49 0.50
Proportion of parous with age of first birth ≥ 25 y and < 30 y 0.30 0.30 0.26 0.29
Proportion of parous with age of first birth ≥ 30 y 0.14 0.11 0.15 0.10
Controls (n) in each coffee consumption category 270 1,171 846 363
Education, categorical
Proportion of highest education level
to elementary school 0.39 0.52 0.50 0.50 0.041
- junior secondary school 0.25 0.22 0.23 0.24
- high school 0.19 0.14 0.14 0.15
- university 0.18 0.12 0.12 0.11
Controls (n) in each coffee consumption category 269 1,168 843 362
Physical activity one year before recruitment, categorical
- none 0.17 0.19 0.16 0.22 0.624
- < 1 h per week 0.18 0.17 0.15 0.16
- 1 to 2 h per week 0.31 0.31 0.34 0.26
- > 2 h per week 0.35 0.33 0.36 0.36
Controls (n) in each coffee consumption category 267 1,165 842 362
aTo obtain P-value for trend for coffee consumption treated as a continuous variable, linear regression analysis was performed for continuous risk factor variables
(age at menarche (years), age at menopause (years), body mass index (kg/m
2) and alcohol consumption (g/day)), logistic regression analysis was performed for
binary risk factor variables (hormone replacement therapy, family history of breast cancer and smoking), and proportional odds logistic regression was performed
for categorical risk factor variables (parity/age at first birth, highest education level, and physical activity one year before enrolment).
SD, standard deviation; y, year(s).
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Page 6 of 10using the Swedish data, we attempted to validate the
results in the independent MARIE study, conducted in
Germany. Though not reaching statistical significance,
the strongest protective effect from heavy coffee con-
sumption was similarly observed for the ER-negative
subtype (OR> 5 cups/day:≤1c u p / d a y : 0.67 (0.43, 1.05), P =
0.326) in the validation study.
We believe that, collectively, the results from the two
studies in this paper support a protective effect of high
intakes of coffee against ER-negative breast cancer. The
weaker associations found within the MARIE study may
perhaps be attributed to other factors related to coffee
drinking, such as brewing method, bean type, and caf-
feine content. For example, Nilsson et al.[ 2 6 ]f o u n d
potentially relevant chemical differences between filtered
and boiled coffee. While a statistically significant
decreased risk of breast cancer was observed in women
drinking boiled coffee, filtered coffee was not found to
be associated with the risk of breast cancer. One possi-
ble explanation of the weaker association with breast
cancer risk in the MARIE study may thus be due to the
primarily use of filtered coffee in Germany, and boiled
coffee in Scandinavia [27].
Several other studies have also examined the relation-
ship between direct measurements of coffee consump-
tion or related variables and risk of ER-positive and ER-
negative breast cancers. Some have reported results that
are in accordance with the findings in this study. For
example, a study by Larsson et al. [28] observed non-
significant trends of increased ER-positive breast cancer
risk and decreased ER-negative breast cancer risk with
increased coffee intake per day in an independent Swed-
ish cohort. Ganmaa et al. [29] observed a general pro-
tective effect of caffeine intake on breast cancer risk for
Table 3 Results of multivariate analysis in Swedish study, overall and stratified by hormone receptor status
Type of breast cancer Daily coffee consumption Controls/Cases OR
a 95% CI OR
bc 95% CI
All ≤ 1 cup 270/298 1.00 reference 1.00 reference
> 1 to 3 cups 1,171/,277 1.00 0.83 1.20 1.01 0.84 1.23
> 3 to 5 cups 846/904 0.96 0.79 1.16 1.00 0.82 1.22
> 5 cups 363/328 0.80 0.64 0.99 0.84 0.66 1.06
P trend 0.028 0.127
ER-positive ≤ 1 cup 270/161 1.00 reference 1.00 reference
> 1 to 3 cups 1,171/685 0.99 0.80 1.23 1.03 0.82 1.30
> 3 to 5 cups 846/501 0.99 0.79 1.23 1.07 0.84 1.36
> 5 cups 363/169 0.77 0.59 1.00 0.87 0.65 1.15
P trend 0.065 0.471
ER-negative ≤ 1 cup 270/48 1.00 reference 1.00 reference
> 1 to 3 cups 1,171/148 0.74 0.52 1.05 0.77 0.53 1.11
> 3 to 5 cups 846/92 0.58 0.40 0.85 0.60 0.40 0.89
> 5 cups 363/31 0.44 0.27 0.71 0.43 0.25 0.72
P trend 0.0002 0.0003
PR-positive ≤ 1 cup 270/135 1.00 reference 1.00 reference
> 1 to 3 cups 1,171/603 1.04 0.83 1.31 1.05 0.83 1.34
> 3 to 5 cups 846/434 1.01 0.80 1.29 1.09 0.85 1.40
> 5 cups 363/144 0.77 0.58 1.02 0.84 0.62 1.13
P trend 0.055 0.360
PR-negative ≤ 1 cup 270/66 1.00 reference 1.00 reference
> 1 to 3 cups 1,171/212 0.75 0.55 1.02 0.85 0.61 1.17
> 3 to 5 cups 846/150 0.71 0.52 0.98 0.75 0.53 1.05
> 5 cups 363/55 0.59 0.40 0.88 0.67 0.44 1.01
P trend 0.014 0.034
aOdds ratio (OR) and corresponding 95% confidence intervals (CI) adjusted for matching factor (age at enrolment in years, continuous).
bORs and corresponding 95% CI adjusted for age at enrolment, potential confounders (hormone replacement therapy (HRT), ever/never, ever smoked > 1 y or>
100 cigarettes, and education (elementary school, junior secondary school, high school or university)) and average daily alcohol consumption (g/day).
Significant P values are in bold.
ER, estrogen receptor; PR, progesterone receptor.
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Page 7 of 10both ER subtypes in the Nurses’ Health Study, but the
effect was only found to be significant for ER-positive
breast cancers. On the other hand, caffeine intake was
significantly associated with a higher risk of ER-negative
breast cancer in the Women’s Health study [30].
Although the results may appear inconsistent, it could
be because no direct comparisons may be made between
the different coffee-related variables measured. For
instance, caffeine is only one out of the many different
compounds contained in coffee, and thus caffeine intake
is perhaps not a valid substitute for measuring the total
effects of coffee consumption.
We speculate that coffee might contain compounds
that differentially affect breast cancer of different ER
subtypes. For example, trigonelline, a phytoestrogen pre-
sent in coffee extract, has been suggested to activate ER
through an estrogen-independent mechanism [9]. This
compound is biologically active and is capable of stimu-
lating cell growth of an ER-positive cell line at low con-
centrations. In addition, coffee has been shown to
significantly contribute to levels of plasma enterolactone
[31], a different phytoestrogen reported to be associated
with a significant decrease in ER-negative breast cancer
risk [12]. The presence of such compounds that specifi-
cally aggravate the tumourigenesis of ER-positive breast
cancer and attenuates the risk of ER-negative breast
cancer corroborates our finding that coffee consumption
decreases breast cancer risk overall (both ER-negative
and ER-positive), but the protection is less evident for
the ER-positive subtype.
A limitation of our study is that receptor status was
available for only 65.4% of the Swedish population. We
Table 4 Validation results in the German MARIE study
Type of breast cancer Daily coffee consumption Controls/cases OR
a (95% CI) OR
b (95% CI)
All ≤ 1 cup 2,148/1,086 1.00 reference 1.00 reference
> 1 to 3 cups 2,136/1,050 0.97 (0.88 to 1.08) 0.97 (0.87 to 1.07)
> 3 to 5 cups 748/358 0.94 (0.82 to 1.09) 0.95 (0.82 to 1.10)
> 5 cups 363/157 0.85 (0.70 to 1.04) 0.87 (0.71 to 1.07)
P trend 0.128 0.173
ER-positive ≤ 1 cup 2,148/854 1.00 reference 1.00 reference
> 1 to 3 cups 2,136/822 0.96 (0.86 to 1.08) 0.95 (0.85 to 1.07)
> 3 to 5 cups 748/279 0.93 (0.79 to 1.09) 0.94 (0.80 to 1.10)
> 5 cups 363/129 0.90 (0.72 to 1.12) 0.92 (0.74 to 1.15)
P trend 0.221 0.302
ER-negative ≤ 1 cup 2,148/214 1.00 reference 1.00 reference
> 1 to 3 cups 2,136/212 1.00 (0.82 to 1.22) 1.02 (0.83 to 1.24)
> 3 to 5 cups 748/76 1.04 (0.79 to 1.36) 1.04 (0.78 to 1.37)
> 5 cups 363/25 0.67 (0.44 to 1.03) 0.67 (0.43 to 1.05)
P trend 0.288 0.326
PR-positive ≤ 1 cup 2,148/737 1.00 reference 1.00 reference
> 1 to 3 cups 2,136/686 0.93 (0.83 to 1.05) 0.92 (0.82 to 1.04)
> 3 to 5 cups 748/239 0.93 (0.78 to 1.10) 0.93 (0.78 to 1.10)
> 5 cups 363/115 0.93 (0.74 to 1.17) 0.96 (0.76 to 1.20)
P trend 0.299 0.363
PR-negative ≤ 1 cup 2,148/332 1.00 reference 1.00 reference
> 1 to 3 cups 2,136/348 1.06 (0.90 to 1.24) 1.06 (0.90 to 1.25)
> 3 to 5 cups 748/116 1.01 (0.80 to 1.26) 1.02 (0.81 to 1.28)
> 5 cups 363/39 0.68 (0.48 to 0.97) 0.70 (0.49 to 1.00)
P trend 0.194 0.280
Multivariate-adjusted OR estimates and corresponding 95% CIs of postmenopausal breast cancer for coffee consumption in the German MARIE study, overall and
stratified by breast cancer tumour subtype based on ER and PR status.
aOdds ratio (OR) and corresponding 95% confidence intervals (CI) adjusted for matching factors age at enrolment in years (continuous) and study region.
bOR and corresponding 95% CI adjusted for age at enrolment in years (continuous) and study region potential confounders (hormone replacement therapy (HRT,
ever/never), ever smoked > 100 cigarettes, and education (low, medium, high) and average daily alcohol consumption (continuous, in g/day)).
ER, estrogen receptor; PR, progesterone receptor.
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cases with and without ER status (Table S1 in Addi-
tional file 1), and found no significant difference
between the two groups, with the exception of age at
first birth (P = 0.0393) and highest education level
attained (P = 0.0003). The coffee consumption variable
and risk factor data of both studies were self-reported,
and could thus be subjected to errors in measurement.
However, correlations between data collection via food
frequency questionnaires and weekly diet records are
generally high [28,32]. Coffee intake also tends to be
very consistent from day to day over longer periods, and
may thus be better recalled, thus strengthening the pre-
sent analysis. In addition, we had limited our analyses to
coffee consumption of cases and age-matched controls
to before breast cancer diagnosis of cases to avoid the
p o t e n t i a lb i a sd u et oac h a n g ei nt h ed i e t a r yh a b i t s
resulting from disease diagnosis. Another concern is the
availability of different kinds of coffee on the market -
caffeinated, decaf, instant and brewed, among others.
According to the European Coffee Report 2008 [33],
decaffeinated coffee makes up 8.25% of the total trade
of roasted coffee, while consumption of decaffeinated
coffee in Sweden is negligible: less than 1%. However,
the analysis of the MARIE study was only limited to caf-
feinated coffee.
Strengths of our study include it being a population-
based study, its large sample size and detailed information
on relevant variables: coffee consumption, reproductive
and hormonal risk factors, and tumour characteristics. We
have also obtained supporting evidence in a large, well-
described and independent population-based study.
Conclusions
In conclusion, we found no evidence that coffee con-
sumption increases the overall risk of postmenopausal
breast cancer. However, a high daily intake of coffee was
found to be associated with a significant decrease in ER-
negative breast cancer among postmenopausal women.
Future studies are needed to confirm the effects of cof-
fee consumption in the light of breast cancer subtypes.
Additional material
Additional file 1: Table S1. Descriptive characteristics of post-
menopausal women with information on hormone receptor status and
without.
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